Antiretroviral Therapy Does Not Block the Secretion of the Human Immunodeficiency Virus Tat Protein

Publisher： Bentham Science Publishers

E-ISSN： 2212-3989|12|1|81-86

ISSN： 1871-5265

Source： Infectious Disorders - Drug Targets (Formerly Current Drug Targets - Infectious Disorders), Vol.12, Iss.1, 2012-02, pp. : 81-86

Disclaimer: Any content in publications that violate the sovereignty, the constitution or regulations of the PRC is not accepted or approved by CNPIEC.

Previous Menu Next

Abstract

Related content

Does mitochondrial dysfunction during antiretroviral therapy in human immunodeficiency virus infection suggest antioxidant supplementation as a beneficial option?

By Gil Lizette   Pérez Daniel   Tápanes Rolando   Pérez Jorge   Grune Tilman  

Redox Report, Vol. 10, Iss. 3, 2005-06 ,pp. : 113-119

Maney Publishing

Access to resources Recommend Favorite

The Pathology Induced by Highly Active Antiretroviral Therapy Against Human Immunodeficiency Virus: an Update

By  

Current Medicinal Chemistry, Vol. 13, Iss. 26, 2006-11 ,pp. : 3121-3132

Bentham Science Publishers

Access to resources Recommend Favorite

Emerging Drug Toxicities of Highly Active Antiretroviral Therapy for HumanImmunodeficiency Virus (HIV) Infection

By  

Current Drug Targets, Vol. 4, Iss. 1, 2003-01 ,pp. : 13-22

Bentham Science Publishers

Access to resources Recommend Favorite

A phase 1/pharmacokinetic study of sunitinib in combination with highly active antiretroviral therapy in human immunodeficiency virus-positive patients with cancer: AIDS Malignancy Consortium trial AMC 061

By Rudek Michelle A.   Moore Page C.   Mitsuyasu Ronald T.   Dezube Bruce J.   Aboulafia David   Gerecitano John   Sullivan Ryan   Cianfrocca Mary E.   Henry David H.   Ratner Lee   Haigentz Missak   Dowlati Afshin   Little Richard F.   Ivy Susan Percy   Deeken John F.  

Cancer, Vol. 120, Iss. 8, 2014-04 ,pp. : 1194-1202

Blackwell Publishing

Access to resources Recommend Favorite

Prognostic factors for advanced-stage human immunodeficiency virus-associated classical Hodgkin lymphoma treated with doxorubicin, bleomycin, vinblastine, and dacarbazine plus combined antiretroviral therapy: A multi-institutional retrospective study

By Castillo Jorge J.   Bower Mark   Brühlmann Jérémy   Novak Urban   Furrer Hansjakob   Tanaka Paula Y.   Besson Caroline   Montoto Silvia   Cwynarski Kate   Abramson Jeremy S.   Dalia Samir   Bibas Michele   Connors Joseph M.   Furman Michael   Nguyen Minh-Ly   Cooley Timothy P.   Beltran Brady E.   Collins Jaime A.   Vose Julie M.   Xicoy Blanca   Ribera Josep-Maria   Castillo Jorge J.  

Cancer, Vol. 121, Iss. 3, 2015-02 ,pp. : 423-431

Blackwell Publishing

Access to resources Recommend Favorite